Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells.
Quantitative studies of MCF-7 cells (derived from human breast adenocarcinoma) and CV-1 cells (from normal African green monkey kidney epithelium), using the permeant cationic compound tetraphenylphosphonium (TPP), in conjunction with fluorescence microscopy using rhodamine 123 (Rh123), indicate that the mitochondrial and plasma membrane potentials affect both uptake and retention of these compounds. Under conditions that depolarize the plasma membrane, uptake and retention of TPP and Rh123, driven only by the mitochondrial membrane potential, is greater in MCF-7 than in CV-1. An ionophore that dissipates the mitochondrial membrane potential of MCF-7 cells causes them to resemble CV-1 cells by decreasing uptake and retention. Hyperpolarizing the mitochondrial membrane of CV-1 increases accumulation and prolongs retention; hyperpolarization of the plasma membrane further heightens this effect, causing the uptake of CV-1 cells to resemble that of MCF-7 cells even more closely. The greater uptake and retention by MCF-7 appears to be a consequence of elevated mitochondrial and plasma membrane potentials. The plasma membrane potential affects mitochondrial retention of TPP and Rh123 and its role in enhancing the effect of a difference in mitochondrial membrane potential is explained.
D000230:Adenocarcinoma / Q000378:metabolism*; D000818:Animals; D001943:Breast Neoplasms / Q000378:metabolism*; D002460:Cell Line; D002522:Chlorocebus aethiops; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008564:Membrane Potentials; D008928:Mitochondria / Q000502:physiology*; D009550:Nigericin / Q000494:pharmacology; D009861:Onium Compounds / Q000378:metabolism; D009943:Organophosphorus Compounds / Q000378:metabolism; D010042:Ouabain / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D020112:Rhodamine 123; D012235:Rhodamines / Q000378:metabolism*; D012964:Sodium / Q000378:metabolism; D014634:Valinomycin / Q000494:pharmacology; D014966:Xanthenes / Q000378:metabolism*
D009861:Onium Compounds; D009943:Organophosphorus Compounds; D012235:Rhodamines; D014966:Xanthenes; D020112:Rhodamine 123; D014634:Valinomycin; D010042:Ouabain; D012964:Sodium; D009550:Nigericin; D011188:Potassium; C013289:tetraphenylphosphonium